GIGALLOLINE
LIVE

Serial Number

79390168

Owner

TREEFROG THERAPEUTICS

Attorney

Rebeccah Gan

Filing Date

Nov 7, 2023

Add to watchlist:

No watchlists yet
View on USPTO

GIGALLOLINE Trademark

Serial Number: 79390168 • Registration: 7646754

GIGALLOLINE is a trademark filed by TREEFROG THERAPEUTICS on November 7, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

TREEFROG THERAPEUTICS (11 trademarks)

30 Avenue Gustave Eiffel, Bâtiment A

Entity Type: 34

Trademark Details

Filing Date

November 7, 2023

Registration Date

January 14, 2025

Published for Opposition

November 26, 2024

Goods & Services

Stem cells for research; stem cells for scientific purposes; nutrition agents, namely, cell culture reagents for scientific and research use for processing living cells other than for medical purposes; cell culture media other than for medical and veterinary purposes

Pharmaceutical products for the treatment of Parkinson's disease and neurodegenerative diseases, heart failure, diabetes, Non-Alcoholic Steatohepatitis and acute liver failure, Age-related macular degeneration and limbal stem cells deficiencies, traumatic injury and skin burns, spinal cord injuries, Huntington disease, amyotrophic lateral sclerosis, Alzheimer's disease, stroke, burns, cancer, osteoarthritis, Multiple Sclerosis, Radiation Induced Intestinal Injury, Inflammatory Bowel Disease, Liver Disease, Duchenne Muscular Dystrophy, Bone Disease, Renal Disease, Chronic Wounds, Graft-Versus-Host Disease, Sepsis and Respiratory diseases, functional microtissues that facilitate transplantation and graft integration; pharmaceutical preparations for the treatment of Parkinson's disease and neurodegenerative diseases, heart failure, diabetes, Non-Alcoholic Steatohepatitis and acute liver failure, Age-related macular degeneration and limbal stem cells deficiencies, traumatic injury and skin burns, spinal cord injuries, Huntington disease, amyotrophic lateral sclerosis, Alzheimer's disease, stroke, burns, cancer, osteoarthritis, Multiple Sclerosis, Radiation Induced Intestinal Injury, Inflammatory Bowel Disease, Liver Disease, Duchenne Muscular Dystrophy, Bone Disease, Renal Disease, Chronic Wounds, Graft-Versus-Host Disease, Sepsis and Respiratory diseases, functional microtissues that facilitate transplantation and graft integration; stem cells for medical or veterinary use; pluripotent stem cells for medical use intended for cell and gene therapies; cultures of cell media for medical and veterinary use; surgical implants comprised of living tissues obtained from stem cells

Laboratory research in the field of biotechnology; scientific research on stem cells; scientific research on the production of pluripotent stem cells by encapsulation; research and development in the field of stem cells, cell and gene therapy and biotechnology; pharmaceutical research and development; scientific laboratory services; providing information with respect to scientific research in the field of stem cells, cell and gene therapy and biotechnology

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 14, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 14, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 26, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 26, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 20, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 30, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 29, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 28, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 28, 2024 TROA
REFUSAL PROCESSED BY IB
Jul 21, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 28, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jun 28, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 16, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jun 15, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 15, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 27, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 22, 2024 REPR